Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 506 Million EUR | 10.55% |
| 2022 | 457.7 Million EUR | 16.79% |
| 2021 | 391.9 Million EUR | -1.48% |
| 2020 | 397.8 Million EUR | 14.05% |
| 2019 | 348.8 Million EUR | 30.39% |
| 2018 | 267.5 Million EUR | -30.36% |
| 2017 | 384.1 Million EUR | 40.54% |
| 2016 | 273.3 Million EUR | -6.02% |
| 2015 | 290.8 Million EUR | 90.69% |
| 2014 | 152.5 Million EUR | 462.73% |
| 2013 | 27.1 Million EUR | -50.94% |
| 2012 | 55.23 Million EUR | -1.07% |
| 2011 | 55.83 Million EUR | 401.14% |
| 2010 | -18.54 Million EUR | -175.5% |
| 2009 | -6.73 Million EUR | 16.63% |
| 2008 | -8.07 Million EUR | 9.19% |
| 2007 | -8.88 Million EUR | 0.16% |
| 2006 | -8.9 Million EUR | -17.31% |
| 2005 | -7.58 Million EUR | 61.36% |
| 2004 | -19.64 Million EUR | -62.08% |
| 2003 | -12.11 Million EUR | -50.11% |
| 2002 | -8.07 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 558 Million EUR | -8.3% |
| 2024 Q1 | 608.5 Million EUR | 20.26% |
| 2023 Q2 | 603.8 Million EUR | 3.59% |
| 2023 Q3 | 630.4 Million EUR | 4.41% |
| 2023 FY | 506 Million EUR | 10.55% |
| 2023 Q4 | 506 Million EUR | -19.73% |
| 2023 Q1 | 582.9 Million EUR | 27.35% |
| 2022 FY | 457.7 Million EUR | 16.79% |
| 2022 Q3 | 493 Million EUR | 8.4% |
| 2022 Q2 | 454.8 Million EUR | 8.62% |
| 2022 Q4 | 457.7 Million EUR | -7.16% |
| 2022 Q1 | 418.7 Million EUR | 6.84% |
| 2021 Q1 | 417.2 Million EUR | 4.88% |
| 2021 FY | 391.9 Million EUR | -1.48% |
| 2021 Q2 | 426.59 Million EUR | 2.25% |
| 2021 Q3 | 425.9 Million EUR | -0.16% |
| 2021 Q4 | 391.9 Million EUR | -7.98% |
| 2020 Q2 | 403.6 Million EUR | 9.73% |
| 2020 Q1 | 367.8 Million EUR | 5.45% |
| 2020 Q3 | 428.2 Million EUR | 6.1% |
| 2020 Q4 | 397.8 Million EUR | -7.1% |
| 2020 FY | 397.8 Million EUR | 14.05% |
| 2019 Q2 | 305 Million EUR | -1.39% |
| 2019 FY | 348.8 Million EUR | 30.39% |
| 2019 Q4 | 348.8 Million EUR | 1.04% |
| 2019 Q3 | 345.2 Million EUR | 13.18% |
| 2019 Q1 | 309.3 Million EUR | 15.63% |
| 2018 FY | 267.5 Million EUR | -30.36% |
| 2018 Q4 | 267.5 Million EUR | 14.56% |
| 2018 Q2 | 449.8 Million EUR | 4.95% |
| 2018 Q1 | 428.6 Million EUR | 11.59% |
| 2018 Q3 | 233.5 Million EUR | -48.09% |
| 2017 Q3 | 381.5 Million EUR | 8.53% |
| 2017 Q2 | 351.5 Million EUR | 12.52% |
| 2017 Q4 | 384.1 Million EUR | 0.68% |
| 2017 Q1 | 312.4 Million EUR | 14.31% |
| 2017 FY | 384.1 Million EUR | 40.54% |
| 2016 Q1 | 228.7 Million EUR | -21.35% |
| 2016 Q3 | 259.6 Million EUR | 10.37% |
| 2016 FY | 273.3 Million EUR | -6.02% |
| 2016 Q4 | 273.3 Million EUR | 5.28% |
| 2016 Q2 | 235.2 Million EUR | 2.84% |
| 2015 Q3 | 258.9 Million EUR | 2.9% |
| 2015 FY | 290.8 Million EUR | 90.69% |
| 2015 Q4 | 290.8 Million EUR | 12.32% |
| 2015 Q2 | 251.6 Million EUR | 14.68% |
| 2015 Q1 | 219.4 Million EUR | 43.87% |
| 2014 Q2 | 156.9 Million EUR | 118.22% |
| 2014 Q3 | 169.6 Million EUR | 8.09% |
| 2014 Q4 | 152.5 Million EUR | -10.08% |
| 2014 FY | 152.5 Million EUR | 462.73% |
| 2014 Q1 | 71.9 Million EUR | 165.31% |
| 2013 Q3 | 27.4 Million EUR | 416.98% |
| 2013 Q4 | 27.1 Million EUR | -1.09% |
| 2013 FY | 27.1 Million EUR | -50.94% |
| 2013 Q1 | 100 Thousand EUR | -99.82% |
| 2013 Q2 | 5.3 Million EUR | 5200.0% |
| 2012 FY | 55.23 Million EUR | -1.07% |
| 2012 Q3 | -55.5 Million EUR | 5.77% |
| 2012 Q4 | 55.23 Million EUR | 199.53% |
| 2012 Q1 | -70.1 Million EUR | -225.55% |
| 2012 Q2 | -58.9 Million EUR | 15.98% |
| 2011 Q1 | -7.3 Million EUR | 60.63% |
| 2011 Q4 | 55.83 Million EUR | 146.53% |
| 2011 FY | 55.83 Million EUR | 401.14% |
| 2011 Q2 | -6.1 Million EUR | 16.44% |
| 2011 Q3 | -120 Million EUR | -1867.21% |
| 2010 Q4 | -18.54 Million EUR | -95.17% |
| 2010 Q3 | -9.5 Million EUR | -39.71% |
| 2010 Q2 | -6.8 Million EUR | 44.26% |
| 2010 FY | -18.54 Million EUR | -175.5% |
| 2010 Q1 | -12.2 Million EUR | -81.28% |
| 2009 FY | -6.73 Million EUR | 16.63% |
| 2009 Q4 | -6.73 Million EUR | 0.0% |
| 2008 FY | -8.07 Million EUR | 9.19% |
| 2007 FY | -8.88 Million EUR | 0.16% |
| 2006 FY | -8.9 Million EUR | -17.31% |
| 2005 FY | -7.58 Million EUR | 61.36% |
| 2004 FY | -19.64 Million EUR | -62.08% |
| 2003 FY | -12.11 Million EUR | -50.11% |
| 2002 FY | -8.07 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ContraFect Corporation | -6.02 Million USD | 8496.947% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -3110.049% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -12187.447% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -125817.944% |
| SQZ Biotechnologies Company | -36.23 Million USD | 1496.324% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -22466.789% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -1082.436% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 8125.983% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -54473.732% |
| Marizyme, Inc. | 18.56 Million USD | -2624.967% |
| Genus plc | 190.6 Million USD | -165.477% |
| Pharming Group N.V. | 109.8 Million USD | -360.821% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -58720.726% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -41584.241% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -74311.765% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -43693.258% |
| IMV Inc. | 7.67 Million USD | -6496.684% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -9096.83% |
| ONE Bio Corp. | 9.04 Million USD | -5497.323% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -3808.543% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -81202.903% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -50112.56% |
| Biomind Labs Inc. | 711.4 Thousand USD | -71027.155% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -735.732% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -3851.091% |
| Skye Bioscience, Inc. | -5.72 Million USD | 8944.006% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -140568.872% |
| Mesoblast Limited | 55.85 Million USD | -805.864% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -361835.281% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -8858.337% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -2546837.132% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -22879.308% |
| GB Sciences, Inc. | 1.74 Million USD | -28858.7% |
| MultiCell Technologies, Inc. | 90.04 USD | -561972356.686% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 275417.213% |
| HST Global, Inc. | 96.79 Thousand USD | -522665.076% |
| CSL Limited | 10.52 Billion USD | 95.193% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 37.63 Thousand USD | -1344536.071% |
| Halberd Corporation | 144.72 Thousand USD | -349538.269% |
| Enzolytics Inc. | 981.65 Thousand USD | -51445.552% |
| Resverlogix Corp. | 6.45 Million USD | -7743.745% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 75275.794% |
| argenx SE | -2.02 Billion USD | 124.94% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 1176.321% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -1556.084% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 5824.039% |
| Bioxytran, Inc. | 1.89 Million USD | -26546.81% |
| Zenith Capital Corp. | 10.06 Thousand USD | -5027721.94% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -21106.739% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -307481.956% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 2762410.296% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | -1.06 Billion USD | 147.676% |
| Kadimastem Ltd | -253.1 Thousand USD | 200019.4% |
| Helix BioMedix, Inc. | -2.57 Million USD | 19788.471% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -25207.694% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -2395.561% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -22531.396% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -375719.785% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 69039.396% |
| EV Biologics, Inc. | 1.36 Million USD | -36889.088% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -251323.574% |
| Q BioMed Inc. | 4.06 Million USD | -12363.03% |
| LadRx Corporation | -2.03 Million USD | 24946.929% |
| Cell Source, Inc. | 9.23 Million USD | -5380.953% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 2479519.835% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -79564.088% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -1064.986% |
| Itoco Inc. | 228.3 Thousand USD | -221533.341% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -371988.919% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -245272.593% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -7056.018% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -10107.787% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -18581.134% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | 8671.612% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -252354.698% |
| NovAccess Global Inc. | 2.17 Million USD | -23127.364% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 78207209.737% |
| BioStem Technologies, Inc. | 4.47 Million USD | -11214.82% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 5459545.812% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 38626054.198% |
| Qrons Inc. | 351.42 Thousand USD | -143884.384% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -6466.31% |
| SYBLEU INC | 473.71 Thousand USD | -106715.505% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 202808.116% |
| Rebus Holdings, Inc. | 305 Thousand USD | -165801.639% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -79564.088% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -11252.872% |
| Affymax, Inc. | -5.59 Million USD | 9140.557% |
| Mobile Lads Corp. | 484.23 Thousand USD | -104395.366% |
| International Stem Cell Corporation | 2.59 Million USD | -19436.68% |
| CytoDyn Inc. | 20.26 Million USD | -2397.286% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -810628.534% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -23101.431% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -14635.003% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -5816.053% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -65392.547% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 40580.0% |
| Neutra Corp. | 52.18 Thousand USD | -969490.128% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 20429.45% |
| PureTech Health plc | -167.19 Million USD | 402.637% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 206708.196% |
| IXICO plc | -4.44 Million USD | 11484.635% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -3727.824% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -822.499% |
| CSL Limited | 10.52 Billion USD | 95.193% |
| Cellectis S.A. | -43.81 Million USD | 1254.754% |